Acadia is seeking regulatory approval in the European Union of trofinetide, sold in the U.S. as Daybue, for patients with Rett syndrome.| Rett Syndrome News
Daybue last year became the first Rett syndrome treatment to win U.S. Food and Drug Administration approval, and is up for approval in Canada.| Rett Syndrome News
Long-term treatment with Daybue (trofinetide) led to continual improvements in symptoms in people with Rett syndrome in extension studies, data show.| Rett Syndrome News